Mutations in the proofreading domains of the replicative DNA polymerases polδ and polε are associated with elevated mutation rates in cancer, but the roles of other DNA polymerases in tumorigenesis remain poorly understood. One such polymerase is polκ, an enzyme that plays a key role in translesion synthesis. polκ contributes to cell survival in the face of DNA damage but can be highly mutagenic due to lack of a proofreading domain. Here we demonstrate that cancer cells under stress from oncogene inhibition upregulate polκ and shift its localization from the cytoplasm to the nucleus. This effect can be phenocopied by mTOR inhibition or glucose deprivation, analogous to stress-induced mutagenesis in E. coli whereby cell stress and nutrient deprivation can upregulate and activate DinB/pol IV (the bacterial orthologue of polκ). We find that cancer cells normally sequester polκ in the cytoplasm via exportin-1, likely to prevent excess mutagenesis from the error-prone nature of this polymerase. Subverting the normal nuclearcytoplasmic shuttling by forced overexpression of nuclear polκ increases resistance of melanoma cells to the BRAF V600E inhibitor vemurafenib. This data suggests a mechanism by which cancer cells regulate the expression and localization of the error-prone polymerase polκ, abrogation of which can contribute to drug resistance.
Introduction
Errors in DNA replication can lead to increased mutation rates, thereby contributing to cancer pathogenesis. For example, somatic or germline mutations in the proofreading domain of DNA polymerase delta (polδ) or epsilon (polε) can lead to tumors with markedly increased numbers of point mutations (1-3). Aside from these two main replicative polymerases, a number of other DNA polymerases have been identified that may contribute to cancer initiation or progression (4) . For example, inactivation of DNA polymerase eta (polη) is associated with xeroderma pigmentosum variant (XP-V), which predisposes patients to UV-induced skin cancers (5) .
Additionally, DNA polymerase iota (polι) is upregulated in esophageal squamous cell cancer, and its expression levels positively correlate with lymph node metastasis/clinical stage (6) .
The roles of other DNA polymerases in this process are less well understood but likely could contribute to tumor progression. One such polymerase is DNA polymerase kappa (polκ), which is a member of the Y-family of DNA polymerases that plays an essential role in the DNA damage tolerance process of translesion synthesis (7, 8) . Several previous studies have shown that overexpression of polκ can contribute to tumorigenesis and drug resistance in cancer (9) (10) (11) (12) .
For example, overexpression of polκ in glioblastoma cells increases resistance to the DNAdamaging agent temozolomide (12) , and it has also been found to be significantly overexpressed in lung cancer (9) . polκ can replicate DNA in both an error-free and error-prone manner during translesion synthesis (13) . It can bypass thymine glycols in a relatively error-free manner (14) , whereas it bypasses N-2-acetylaminofluorene adducts in a more error-prone manner (15) . When replicating on 4 undamaged DNA, polκ has a markedly high error rate due to a relatively large active site and lack of a proofreading domain (16) . Using in vitro assays, it has been shown to have error rates as high as 1 error per 200 base pairs when replicating on undamaged DNA (17) . For this reason, it is considered an "error-prone" polymerase that can induce untargeted mutations while acting either directly at the replication fork or by filling in post-replication gaps (18) . The range of errors introduced by polκ span virtually all substitutions, although to differing degrees (with a high rate of T→G substitutions), as well as a preponderance of deletions (16) . These error rates are substantially higher than that found for the replicative polymerases polδ and polε.
Because dysregulated polκ can be mutagenic at high levels, it is important that cells limit both its expression and access to DNA. In bacteria, this regulation is enacted via the SOS/DNA damage response along with the RpoS/starvation stress response (19, 20) . In work spanning several decades, it has been observed that E. coli use a mechanism referred to as stress-induced mutagenesis to temporarily increase their mutation rate under periods of stress (20) (21) (22) (23) . This hypermutation is enacted as part of double-strand DNA break repair, which becomes mutagenic due in part to the activity of DinB (24) , the E. coli orthologue of human polκ. This mutagenic process is regulated at three levels, as recently reviewed (22) : 1) a double-strand break (25, 26) , 2) activation of the SOS DNA damage response (21) , and 3) activation of the generalized sigma S (RpoS) stress response (20) . The SOS response, when coupled with this stress response, allows first for upregulation of DinB (27) and then subsequent usage of this error-prone polymerase for mutagenic repair, which results in the base substitutions and indels that are commonly observed (20) . It is likely that deficiencies in mismatch repair contribute to this process since overexpression of MutL inhibits mutation in stationary phase but not during growth (28), 5 whereas both MutS and MutH can be downregulated in part by the stress response RpoS pathway (29) .
In contrast to the work in E. coli, the mechanisms regulating the expression and localization of polκ in mammalian cells remains poorly understood. In normal human tissues, polκ is widely expressed at the mRNA level (30) , whereas in the mouse, it is highly enriched in the adrenal cortex and testis (31) . In the mouse, protein expression using a peptide-generated antibody was noted in adrenal cortex, pachytene cells in meiosis I, post-meiotic spermatids, and some epithelial cells in the lung and stomach (31) . At the cellular level, numerous studies using overexpression of EGFP-polκ fusion proteins have demonstrated that polκ is strongly enriched in the nucleus (32, 33) . However, antibody staining of endogenous polκ protein using antibodies generated with either peptide fragment or full-length proteins have shown variable expression in both the cytoplasm as well as the nucleus (31) . Analysis of the polκ promoter has shown consensus binding sites for Sp1 and CREB, both of which have been reported to transcriptionally activate its expression (34, 35) .
Although recent observations demonstrate that polκ is mutagenic and can promote tumorigenesis and drug resistance (9) (10) (11) (12) , it is unknown what regulates its expression in cancer. Ectopic expression of polκ allows it to become part of the replication machinery, even in the absence of external stress, indicating that high levels of it alone may be sufficient to induce new mutations (32) . This has important clinical implications since dysregulation of polκ expression could therefore contribute to tumorigenic phenotypes by affecting its normal subcellular localization.
In this study, we demonstrate that deprivation of oncogenic signaling in melanoma, lung, and 6 breast cancer cell lines upregulates polκ and confines it to the nucleus. These pathways converge on PI3K/mTOR signaling, a central regulator of nutrient status in the cell (36) that may be analogous to the generalized stress factor sigma S in E. coli (22) . When cells are nutrient replete and have intact mTOR signaling, polκ is primarily present in the cytoplasm; when cells are starved or mTOR is inhibited, polκ shifts primarily to the nucleus, suggesting that the cell can dynamically regulate polκ in response to cell stress. In line with this, we find that polκ can be rapidly exported back out of the nucleus via the nuclear export machinery, implying that cells may normally use nuclear export to prevent excess mutagenesis. When this dynamic regulation is subverted by forced nuclear overexpression of polκ, we find that this increases resistance to the BRAF V600E inhibitor vemurafenib in melanoma cells. Our data suggest a mechanism by which mammalian cancer cells regulate the levels and localization of the error-prone DNA polymerase polκ, dysregulation of which can contribute to drug resistance.
Results

MAPK inhibition induces polκ mRNA upregulation and changes the subcellular localization of its protein
Given the role of stress in upregulating DinB/pol IV in E. coli, we first asked whether cell stress regulated polκ expression in cancer. We reasoned that drugs blocking oncogenic drivers would induce cell cycle arrest and ultimately apoptosis and would represent an extreme form of cell stress. In human melanoma, the most common activating mutation occurs at BRAF V600E , which activates downstream MAP kinase signaling via MEK/ERK signaling. This provides the melanoma cells with a significant growth advantage. Small molecules targeting the BRAF/MEK/ERK pathway have been developed, some of which are being clinically used to treat melanoma patients (37) (38) (39) . BRAF inhibitors such as vemurafenib can induce cell stress prior to overt death of the cancer cell, which can occur via the ER stress pathway (40) and is associated with stress-induced senescence (41) . Based on this, we first asked whether inhibition of the MAP kinase pathway could induce polκ expression in melanoma.
To assess this, we treated the BRAF V600E mutant melanoma A375 cell line with the BRAF V600E kinase inhibitor PLX4032 (vemurafenib) (37) and measured polκ by qRT-PCR from 2-72 hours post exposure. This revealed an upregulation in expression of polκ that peaks at 24 hours and is sustained thereafter (Fig. 1A) . We next examined expression of polκ at the protein level under similar conditions. We utilized an antibody raised against full-length human polκ protein and verified its specificity using shRNA knockdown and overexpression of endogenous polκ (Fig.   S1 , A to C). Although polκ has been largely reported to be nuclear localized when overexpressed as an EGFP-tagged fusion protein (32, 33) , we surprisingly found that the Western blot using an 8 antibody raised against the full-length protein showed that endogenous polκ was expressed in both cytoplasmic and nuclear fractions (Fig. 1B ). This expression pattern is similar to that of the related family member pol eta (polη), where both cytoplasmic and nuclear expression is seen (Human Protein Atlas (42)). While treatment with vemurafenib did not change overall protein levels of polκ, it instead induced a specific increase in nuclear polκ and corresponding decrease in cytoplasmic polκ (Fig. 1, B 
DNA damage or cell cycle arrest are not sufficient for polκ localization
The induction of DinB in bacteria relies upon two related systems: the SOS/DNA damage response and the RpoS-controlled general/starvation stress response. We reasoned that the nuclear localization of polκ in response to MAP kinase inhibition might act through one of these two mechanisms. To test this, we treated A375 melanoma cells with vemurafenib and then checked for markers of DNA damage (46) , including gamma H2AX (γH2AX), 53BP1, phosphorylated Chk1 (p-Chk1), and phosphorylated Chk2 (p-Chk2) ( Fig. S3A ) but saw no 9 induction of any of these markers. We also tested whether knockdown of p53, which is a regulator of the DNA damage response pathway (47) , would prevent the observed subcellular shift but failed to see any change in the nuclear localization of polκ after treatment with PLX4032 ( Fig. S3 , B to D). Another possibility was that cell cycle arrest was the signal, as would be expected during a starvation response or during MAPK inhibition. To test this, we treated A375 melanoma cells with either the CDK4/6 inhibitor PD0332991 (48) or the BRAF V600E inhibitor vemurafenib and then assessed the cell cycle using flow cytometry and polκ localization using immunofluorescence. As expected, both of these interventions led to a near complete G1 arrest; however, treatment with the CDK4/6 inhibitor resulted in little to no nuclear polκ ( Fig. S4 , A to C). Taken together, these data suggested to us that other mechanisms might be responsible for the induction of polκ.
mTOR inhibition rapidly induces polκ nuclear accumulation
As we saw no effect of cell cycle inhibition or DNA damage, we next turned to mTOR signaling, a central sensor and effector of growth factor signaling, nutrient status, and stress (36) . The mTOR pathway can be activated by RAF/MEK/ERK signaling either directly or via crosspathway activation (49) (50) (51) (52) . In addition, BRAF inhibition with vemurafenib has recently been shown to induce the ER stress response (40, 53) , which is associated with suppression of mTOR signaling (54) . Based on this, we reasoned that MAPK inhibition might be acting to dampen downstream mTOR signaling to mediate the effect on polκ. To test this, we treated A375 melanoma cells with inhibitors of BRAF/MEK/ERK signaling for 24 hours and then measured mTOR pathway activation via levels of phosphorylated S6 (p-S6), a target of S6K (36, 55) . We found that these MAPK inhibitors potently decreased levels of p-S6 ( 
polκ dysregulation occurs in other cancer types
We next wished to determine if the observed effects on polκ were specific to melanoma/the BRAF pathway, or if they could be applied more broadly. To test this, we examined polκ mRNA levels and subcellular localization in breast and lung cancer cell lines, which harbor unique oncogenic dependencies that differ from melanoma. PC-9 lung cancer cells harbor activating mutations in EGFR and are critically dependent upon that growth factor signaling pathway. We treated PC-9 cells with either the EGFR inhibitor erlotinib (56) or the BRAF V600E inhibitor PLX4032 (which we would expect to have no effect as these cells contain wild-type BRAF) and then measured the expression of polκ and determined its localization. Both high and low doses of erlotinib caused induction of polκ mRNA and a shift of polκ to the nucleus in the PC-9 cells, but as expected, this effect was not seen with PLX4032 (Fig. 3, A and B and Fig. S6A ). Analogous to what we observed for melanoma, this shift of polκ to the nucleus was accompanied by a loss of p-S6 in the lung cancer cells (Fig. 3 , A and C). A similar effect was seen in a breast cancer cell line. SK-BR3 cells, which overexpress the HER2 oncogene, were treated with the HER2 inhibitor lapatinib (57) or the BRAF V600E inhibitor PLX4032. Lapatinib caused a marked induction of polκ expression, nuclear accumulation of polκ, and suppression of p-S6 (Fig. 3 , D to F and Fig. S6B ), an effect that was not seen with PLX4032 in this cell line as expected. These results demonstrate that the observed effects on polκ are specific to the driver oncogene, and that they can be generalizable to multiple cancer types.
Glucose starvation phenocopies the effects on subcellular localization of polκ mTOR could elicit the observed effect on polκ through multiple downstream mechanisms, but because E. coli use the starvation response as part of DinB upregulation/activation, we wondered whether by inhibiting mTOR, we were mimicking a starvation response. To test this idea, we examined the effect of nutrient deprivation on polκ localization. We grew A375 melanoma cells in a variety of media conditions in which we selectively removed serum, glucose, or glutamine and measured polκ localization by immunofluorescence. Whereas we found that both glutamine and serum deprivation had small effects on nuclear polκ localization, glucose starvation resulted in a highly significant induction of nuclear polκ (Fig. S7, A and B) . Because glucose is a major carbon source for rapidly growing cancer cells, this may be analogous to the starvation response induced in E. coli by deprivation of lactose, which is an important carbon source for bacteria.
Exportin-1 plays a role in regulating the subcellular localization of polκ
This data led us to ask what mechanisms the cells may use to control cytoplasmic versus nuclear localization of polκ. A previous analysis of the protein structure of polκ demonstrated that the full-length protein contains a bipartite nuclear localization signal (NLS) towards the 3' end of the gene (30, 33) , and computational analysis (58) also indicated a likely nuclear export signal (NES). Deletion of the NLS region results in the protein completely localizing to the cytoplasm (33) , which suggested to us that the localization results we saw above might be controlled by the nuclear import and/or export machinery. To test this, we utilized inhibitors of importin-β or exportin-1 (CRM1) and tested whether these affected the shift of polκ in response to BRAF inhibition in melanoma cells. We found that importazole (59), which inhibits importin-β, had little effect on polκ localization (Fig. S8, A and B) . In contrast, co-treatment with leptomycin B (60), which inhibits exportin-1, accelerated the rate at which polκ localized to the nucleus: whereas 3 hours of PLX4032 typically only leads to ~30% induction of nuclear polκ, in the presence of leptomycin B, this increased to 60% (Fig. 4, A and B ). In addition, we noted that leptomycin B alone (even in the absence of PLX4032) induced a small but significant increase in nuclear polκ, indicating that polκ normally cycles between the cytoplasm and nucleus. To further test the contribution of the nuclear export machinery, we performed washout experiments. A375 cells were treated with PLX4032 (to induce nuclear polκ) and then the drug was washed away (Fig. 4C ). After washout, polκ relocates to the cytoplasm within 24 hours. However, if leptomycin B is added after PLX4032 washout, polκ remains present in the nucleus (Fig. 4, D and E). This data indicates that oncogenic signaling regulates the nuclear localization of polκ (at least in part) through the export machinery.
polκ overexpression can lead to increased drug resistance
These data suggested a model in which rapidly growing cancer cells generally keep polκ at relatively low levels and sequestered in the cytoplasm due to active nuclear export. This is likely important to prevent excess mutagenesis in the absence of a need for translesion synthesis.
Consistent with this idea, it has been previously shown that forced overexpression of polκ leads to sustained nuclear expression, and that this overexpression can be highly mutagenic on its own, i.e. even in the absence of overt DNA damage (32) . We hypothesized that subverting this normal shuttling and forcing polκ to remain nuclear could contribute to drug resistance due to this capacity for inducing new mutations. To test this, we generated a doxycycline-inducible polκ overexpression construct for use in A375 melanoma cells (Fig. 5A) . We then isolated multiple single cell clones from this population and expanded them in culture in the presence or absence of doxycyline for 3 months. As expected, these cells showed strong induction with increased nuclear localization of polκ after addition of doxycycline (Fig. S1 , B and C). We then tested both populations for sensitivity to either the BRAF V600E inhibitor PLX4032 or the CDK4/6 inhibitor PD0332991 (Fig. 5A) . For both clones, the population that had experienced long-term polκ overexpression showed a modest increase in growth in PLX4032 across multiple different doses compared to their respective negative control cells (Fig. 5B) , consistent with increased resistance to the drug. In contrast, there was no significant difference between the two populations with regards to their responses to PD0332991 (Fig. 5C ). This is consistent with the concept that prolonged nuclear expression of polκ is associated with resistance to certain clinically relevant cancer therapeutics, such as BRAF inhibitors.
Discussion
There Several studies have now identified overexpression of polκ in human tumors such as lung cancer or glioblastoma 9, 10 . Because polκ lacks a proofreading domain, its overexpression can be associated with increased mutation rates as well as drug resistance (11, 12) . However, despite the potential importance of polκ in promoting tumor progression, little is known about the mechanisms by which it is regulated. In this study, we identified oncogenic signaling and nutrient status as one potential regulator of polκ expression and localization in cancer.
polκ belongs to a family of related Y-family DNA polymerases which all function in translesion synthesis, a major DNA damage tolerance pathway (7, 8) . In normal physiology, these polymerases play an important role in bypassing stalled replication forks that are induced by DNA damaging agents. Because they all lack proofreading domains, they have a propensity to introduce errors during replication, although depending on the specific lesion, they can also act in an error-free manner. For this reason, these Y-family polymerases can be a double-edged 15 sword since they allow for replication past damaged regions of DNA and cell survival but may do so at a cost of new mutations (68) . in vitro studies have demonstrated that these polymerases can act with extraordinarily low fidelity, with error rates ranging from 10 -1 to 10 -4 , compared to ~10 -6 for the normal replicative polymerases polδ or polε (16, 69, 70) . For this reason, it is important that cells regulate the expression and localization of these polymerases such that they only act when the cell is under genomic stress.
Although DNA damage is likely the major inducer of polκ, our data would suggest that mammalian cells harbor the capacity to induce the expression of polκ under other forms of cell stress, namely loss of oncogenic signaling and/or nutrient starvation. This may be analogous to E. coli, whereby cells under starvation stress can upregulate DinB/pol IV (the bacterial orthologue of polκ) (19, 20) . However, in E. coli, in addition to activating DinB, the RpoS and SOS pathways have other effects on the cells, including suppression of mismatch repair (29) , and all of these processes are necessary to induce new mutations (22) . Additionally, previous work has demonstrated that cancer cells harboring mutations in the proofreading domain of polε also experience loss of mismatch repair enzymes (71) , and more recently it has been shown that suppression of mismatch repair is necessary for these polε mutants to dramatically increase their mutation rates (72) . Surprisingly, in mammalian cells, overexpression of polκ alone has been shown to be highly mutagenic (73) , although the status of mismatch repair was not directly assessed. Although in our studies we did not directly measure mutation rate after prolonged overexpression of polκ, we do see increased resistance to BRAF inhibitors, which is sometimes linked to the emergence of new clones with distinct mutational profiles (74) (75) (76) (77) (78) (79) (80) . These mutations are often, although not always, found to be pre-existing upon deep sequencing (81) . However, it 16 is important to note that we cannot exclude other, non-mutagenic functions of polκ that could account for the increased drug resistance, the elucidation of which will require future evaluation.
One unexpected finding in our study was the observation that polκ can exist in a cytoplasmic form. Numerous prior studies have shown that polκ is primarily a nuclear protein, but these relied upon overexpression of an EGFP-polκ fusion protein (32, 33) . In our hands, overexpression of polκ also strongly upregulated nuclear expression, which we believe likely reflects saturation of the export machinery. This would be consistent with our data using leptomycin B, which suggested that one important mechanism of regulation for polκ is nuclear- Our data indicates that mTOR and nutrient sensing regulate the localization of polκ, and this pathway more broadly is known to affect nuclear-cytoplasmic shuttling of multiple proteins (84) (85) (86) (87) (88) (89) (90) (91) . For example, PI3K/Akt/mTOR signaling has been shown to prevent nuclear accumulation of glycogen synthase kinase 3β (GSK3β) such that inhibition of this pathway leads to a robust increase in nuclear GSK3β (89, 90) . Furthermore, mTORC1-dependent phosphorylation of the transcription factor TFEB promotes association of TFEB with members of the 14-3-3 family of proteins, thereby forcing its retention in the cytosol (88) . However, the network connecting the mTOR pathway to the DNA damage response continues to be elucidated (92) (93) (94) (95) . A recent study (95) showed that mTOR/S6K signaling leads to phosphorylation and subsequent degradation of RNF168, and hyperactivation of mTOR via LKB1 leads to decreased levels of RNF168 and increases DNA damage. One possible explanation for our observed results is that mTOR (or one of its downstream targets) could directly phosphorylate polκ and thereby affect its localization as has been shown for other proteins that undergo nuclear-cytoplasmic shuttling (96) (97) (98) (99) ). An important area for future exploration is understanding the ways in which mTOR may interact with the maintenance of genome stability.
One implication of our study is that polκ may play a role in resistance to targeted therapies. A previous study (12) showed that polκ could mediate resistance to the DNA damaging agent temozolomide, but no studies have directly linked polκ to non-mutagenic therapies such as BRAF V600E inhibitors. Both genetic and non-genetic mechanisms of BRAF inhibitor resistance have been described (74-81, 100, 101) , and many of the mutations that lead to drug resistance are pre-existing in the population when examined by deep sequencing. However, it is also possible that certain forms of cell stress could lead to prolonged overexpression of polκ, resulting 18 in new mutations in the population. Given the fact that the resistance phenotype we saw from such overexpression was modest, it is highly likely that there would need to be other defects in DNA repair for this to become a major mechanism of drug resistance. Such a mechanism may have similarities to the E. coli stress-induced mutagenesis pathway, in which overexpression of DinB/pol IV, in concert with other factors such as downregulation of mismatch repair, can lead to new drug resistance mutations (19) (20) (21) (22) (23) . Given the availability of small molecule inhibitors of polκ (102, 103) , it will be of future interest to determine whether the administration of such inhibitors could forestall the development of resistance to targeted therapies.
Materials and Methods
Cell culture
Cell culture was performed at 37°C in a humidified atmosphere containing 5% CO 2 . A375 and SK-MEL28 cells were obtained from ATCC. PC-9 cells were a gift from C. Rudin (MSKCC, NYC, USA). SK-BR3 cells were a gift from S. Chandarlapaty (MSKCC, NYC, USA). Cells were cultured in DMEM (A375 and SK-MEL28), RPMI1640 (PC-9), or DMEM/F12 (SK-BR3)
supplemented with 2 mM glutamine, 100 IU/ml penicillin, 100 µg/ml streptomycin, and 10%
heat-inactivated fetal bovine serum. Cell lines were regularly tested and verified to be mycoplasma negative by the MycoAlert™ Mycoplasma Detection Kit (Lonza).
Cell treatments
Inhibitors were maintained until collection unless otherwise noted: PLX4032 (Selleck), CI-1040 Media -glutamine consisted of DMEM (without glucose or glutamine) supplemented with 25 mM glucose and 10% heat-inactivated fetal bovine serum. Media + 1% serum consisted of DMEM (without glucose or glutamine) supplemented with 25 mM glucose, 6 mM glutamine, and 1% heat-inactivated fetal bovine serum. and 1 mg/ml hygromycin. Single cell clones were then isolated, and their induction efficiency was tested via flow cytometry. Clones #1 and #2 showed the best induction after addition of 1 µg/ml doxycycline (Sigma Aldrich) compared to uninduced controls, so they were selected for future experiments.
Generation of inducible polκ overexpression cells
Inducible shRNA knockdown of polκ and p53
For inducible knockdown of polκ, two different shRNAs (104) targeting polκ were generated using PCR. The two polκ shRNAs (sh-polκ-1 and sh-polκ-2) were each cloned using restriction digestion and ligation into the LT3GEPIR vector (105) 
Drug resistance assays
Two different clones of doxycycline-inducible polκ overexpression cells (Clone #1 and Clone #2) were generated. We then divided each population equally and treated with or without 1 µg/ml doxycycline for ~3 months to generate polκ-overexpressing cells and their corresponding 25 negative control population. All populations were then switched to media without doxycycline, plated in 96 well plates, and exposed to various doses of PLX4032 or PD0332991. After 4 (PLX4032) or 7 days (PD0332991), cell number was determined using the CyQUANT Direct Cell Proliferation Assay kit (Thermo Fisher Scientific). The technical replicates for each dose were averaged and then normalized against the 0 µM dose condition to determine the growth relative to DMSO.
Statistical tests
The following statistical tests were used: paired 2-tailed t-test (all q-RT-PCR, Western blot analysis, and immunofluorescence), chi-square tests (cell cycle analysis), Pearson correlation coefficient (comparison of rates of p-S6 loss vs. nuclear polκ enrichment), and two-way ANOVA and Fisher's least significant difference (LSD) test (drug resistance assays). Fig. S1 . Validation of the polκ antibody. 
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